Exenatide
ECHO
AstraZeneca · Phase 3 · Completed · Enrollment 42
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Exenatide once weekly extended-release | Obesity or overweight | n/r | 36 | n/r | 1.7% at week 36 |
| Matching placebo | Obesity or overweight | n/r | 36 | n/r | 3.5% at week 36 |